A Promising Drug Pair for Treatment-Resistant Prostate Cancer

A recent preclinical study points to a potentially important strategy for advanced prostate cancer: combining two already-known drugs to attack the disease from different angles at the same time. The work focused on metastatic castration-resistant prostate cancer, one of the hardest forms of prostate cancer to treat because it often adapts after standard hormonal therapies stop working. In this setting, the cancer can rely on alternative survival programs, including androgen receptor splice variants such as AR-V7, which help it keep growing even when traditional treatment pressure is high.

The researchers used a large, unbiased drug screen across advanced prostate cancer models and found that blocking XPO1, a protein involved in nuclear export, created a strong vulnerability. They then discovered that the effect became much stronger when XPO1 inhibition was paired with inhibition of EIF4A1, a factor involved in translation initiation, meaning the step by which cells begin making proteins. In simple terms, the combination interfered with both the movement of key molecules out of the nucleus and the cancer cell’s ability to manufacture proteins it needs to survive.

What makes the finding especially interesting is that the two drugs, eltanexor and zotatifin, were not brand-new experimental ideas from scratch. They were existing agents with known mechanisms, which gives the study a repurposing-like quality, even though the main innovation was the way they were combined rather than a straightforward reuse of one drug for a different disease. That matters because drug repurposing can shorten the path toward clinical testing when the pharmacology, dosing logic, and basic safety profile are already partly understood. In this case, the authors also emphasized that the combination worked at relatively low doses in their models, which may help limit toxicity if the approach ever reaches patients.

The biological effects were striking. The paired treatment reduced AR and AR-V7 signaling, triggered apoptosis, and suppressed growth-related pathways tied to proliferation and metabolism. The same pattern was seen not only in cell lines but also in patient-derived organoids and xenograft models, which strengthens the relevance of the result. In one sense, the study suggests that the cancer’s ability to resist treatment may depend on two separate but cooperating systems: the export machinery that helps regulate where important proteins and RNA go, and the translation machinery that helps the cell keep producing those survival proteins.

Source.